Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "With respect to PDS and TPL, we do not intend to fund any cash requirements of

We may be far better off moving on and using the $10 million we have to engage another 'Alliacense-type' entity and start licensing the MMP ourselves. I hope the BoD is seriously considering this option and would appreciate them addressing with shareholders this strategic option at this critical juncture. If DL doesn't like that, too bad; it is time he starts having to spend his own money chasing us, rather than the other way around.

Share
New Message
Please login to post a reply